New classification and diagnostic criteria for insulin resistance syndrome
- PMID: 35463863
- PMCID: PMC8980125
- DOI: 10.1007/s13340-022-00570-5
New classification and diagnostic criteria for insulin resistance syndrome
Abstract
This report of a working group established by the Japan Diabetes Society proposes a new classification and diagnostic criteria for insulin resistance syndrome. Insulin resistance syndrome is defined as a condition characterized by severe attenuation of insulin action due to functional impairment of the insulin receptor or its downstream signaling molecules. This syndrome is classified into two types: genetic insulin resistance syndrome, caused by gene abnormalities, and type B insulin resistance syndrome, caused by autoantibodies to the insulin receptor. Genetic insulin resistance syndrome includes type A insulin resistance as well as Donohue and Rabson-Mendenhall syndromes, all of which are caused by abnormalities of the insulin receptor gene; conditions such as SHORT syndrome caused by abnormalities of PIK3R1, which encodes a regulatory subunit of phosphatidylinositol 3-kinase; conditions caused by abnormalities of AKT2, TBC1D4, or PRKCE; and conditions in which a causative gene has not yet been identified. Type B insulin resistance syndrome is characterized by severe impairment of insulin action due to the presence of insulin receptor autoantibodies. Cases in which hypoglycemia alone is induced by autoantibodies that stimulate insulin receptor were not included in Type B insulin resistance syndrome.
Keywords: Insulin receptor; Insulin receptor autoantibodies; Type A insulin resistance syndrome; Type B insulin resistance syndrome.
© The Japan Diabetes Society 2022.
Conflict of interest statement
Conflict of interestWataru Ogawa: Lecture fee (Sumitomo Dainippon Pharma Co., Ltd., Novartis Pharma K.K., Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Abbott Japan), Total amount of research expenses (joint research, commissioned research, clinical trials, etc.) and grants (Noster, Nippon Boehringer Ingelheim Co., Ltd., Boehringer Ingelheim Pharma GmbH&Co.KG, Eli Lilly Japan K.K., Novo Nordisk Pharma LTD., Abbott Japan, Abbott Diabetes Care UK Ltd, Sumitomo Dainippon Pharma Co., Ltd.), Total amount of scholarships (incentives) (Kowa Company, Ltd., Novo Nordisk Pharma LTD., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., ONO PHARMACEUTICAL CO., LTD., Takeda Pharmaceutical Co. Ltd., Abbott Japan, Novartis Pharma K.K., DAIICHI SANKYO CO., LTD., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd.), Eiichi Araki: Lecture fees (AstraZeneca, MSD, ONO PHARMACEUTICAL CO., LTD., Kowa Company, Ltd., Sanofi, DAIICHI SANKYO CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk Pharma LTD.) Total amount of scholarships (incentives) (Astellas Pharma Inc., Kowa Company, Ltd., Sanofi, DAIICHI SANKYO CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Novo Nordisk Pharma LTD. Bayer Yakuhin Ltd) Endowed chair (ONO PHARMACEUTICAL CO., LTD., Terumo Corporation), Yasushi Ishigaki: Lecture fees (MSD, Novartis Pharma K.K., Mitsubishi Tanabe Pharma Corporation, Sanofi, ONO PHARMACEUTICAL CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Novo Nordisk Pharma LTD.) Total amount of research expenses (joint research, commissioned research, clinical trials, etc.) and grants (Novo Nordisk Pharma LTD., DAIICHI SANKYO CO., LTD.), Total amount of scholarships (incentives) donations (Novartis Pharma K.K., ONO PHARMACEUTICAL CO., LTD., Takeda Science Foundation), Yushi Hirota: Lecture fee (Eli Lilly Japan K.K. Sanofi), Hiroshi Maegawa: Lecture fees (Sanofi, Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma LTD., Sumitomo Dainippon Pharma Co., Ltd., MSD, Astellas Pharma Inc., DAIICHI SANKYO CO., LTD., AstraZeneca, Eli Lilly Japan K.K.) Total amount of research fees (joint research, commissioned research, clinical trials, etc.) and grants (Nippon Boehringer Ingelheim Co., Ltd., Sunstar, Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co., Ltd. And Cimic Co., Ltd., Nissan Chemical Corporation, MIKI Corporation, Parexel), Total amount of scholarships (incentives) (Takeda Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, DAIICHI SANKYO CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Kowa Company, Ltd., Sanwa Kagakukenkyusho Co, Ltd., Novo Nordisk Pharma LTD., Nipro Corporation, Astellas Pharma Inc., MSD, Taisho Pharma Co., Ltd., ONO PHARMACEUTICAL CO., LTD., Bayer Yakuhin Ltd, Novartis Pharma K.K.), Toshimasa Yamauchi: Lecture fees (Astellas Pharma Inc., AstraZeneca, ONO PHARMACEUTICAL CO., LTD., Sanofi, Takeda Pharmaceutical Co. Ltd., DAIICHI SANKYO CO., LTD., Novartis Pharma K.K., Novo Nordisk Pharma LTD.), Total amount of research expenses (joint research, commission research, clinical trials, etc.) and grants (Astra Zeneca, Kowa Company, Ltd., MSD, DAIICHI SANKYO CO.,LTD., Sanofi, Nippon Boehringer Ingelheim Co.,Ltd., Aero Switch Therapeutics, Inc., Sanwa Kagakukenkyusho Co, Ltd., Minophagen Pharmaceutical Co., LTD., Mitsubishi Corporation Life Sciences Limited, Nipro Corporation), Total amount of scholarships (incentives)(Kissei Pharmaceutical Co., Ltd., Taisho Pharma Co., Ltd., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Sanofi, Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk Pharma LTD., ONO PHARMACEUTICAL CO., LTD., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd., Sanwa Kagakukenkyosho Co, Ltd.), Endowed chair offered by companies, etc. (Takeda Pharmaceutical Co. Ltd., ONO PHARMACEUTICAL CO., LTD., Novo Nordisk Pharma LTD., Mitsubishi Tanabe Pharma Corporation, MSD, Nippon Boehringer Ingelheim Co.,Ltd., Kowa Company, Ltd., NTT Docomo Inc., Asahi Mutual Life Insurance Co), Tohru Yorifuji: Lecture fees (Novo Nordisk Pharma LTD.), Hideki Katagiri: Lecture fees (Mitsubishi Tanabe Pharma Corporation, Sanofi, Novo Nordisk Pharma LTD.), Total amount of research expenses (joint research, commission research, clinical trials, etc.) and grants (Otsuka Pharmaceutical Co., Ltd., Suntory Holdings Limited, Astellas Pharma Inc.), Total amount of scholarships (incentives) donations (Takeda Pharmaceutical Co. Ltd., DAIICHI SANKYO CO., LTD., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Corporation, ONO PHARMACEUTICAL CO., LTD., Eli Lilly Japan K.K., MSD., Sanofi., Novo Nordisk Pharma LTD.)
Similar articles
-
New classification and diagnostic criteria for insulin resistance syndrome.Endocr J. 2022 Feb 28;69(2):107-113. doi: 10.1507/endocrj.EJ21-0725. Epub 2022 Feb 1. Endocr J. 2022. PMID: 35110500
-
Clinical characteristics of insulin resistance syndromes: A nationwide survey in Japan.J Diabetes Investig. 2020 May;11(3):603-616. doi: 10.1111/jdi.13171. Epub 2019 Dec 5. J Diabetes Investig. 2020. PMID: 31677333 Free PMC article.
-
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.Diabetol Int. 2020 Jul 15;12(1):62-67. doi: 10.1007/s13340-020-00455-5. eCollection 2021 Jan. Diabetol Int. 2020. PMID: 33479580 Free PMC article.
-
[Syndromes of severe insulin resistance].Nihon Rinsho. 1999 Mar;57(3):617-21. Nihon Rinsho. 1999. PMID: 10199143 Review. Japanese.
-
Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.Dan Med J. 2014 Jul;61(7):B4890. Dan Med J. 2014. PMID: 25123125 Review.
Cited by
-
Conquering diabetes by overcoming psychological barriers and embracing health.Sci Rep. 2024 Dec 30;14(1):32104. doi: 10.1038/s41598-024-83837-y. Sci Rep. 2024. PMID: 39738997 Free PMC article.
-
A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01).Diabetes Ther. 2024 Feb;15(2):533-545. doi: 10.1007/s13300-023-01526-x. Epub 2024 Jan 13. Diabetes Ther. 2024. PMID: 38216831 Free PMC article.
-
Insulin resistant diabetes mellitus in a girl with mild Rabson-Mendenhall syndrome: efficacy of sodium glucose co-transporter 2 inhibitor.Diabetol Int. 2024 Nov 15;16(1):182-187. doi: 10.1007/s13340-024-00773-y. eCollection 2025 Jan. Diabetol Int. 2024. PMID: 39877435
-
A family with type A insulin resistance syndrome caused by a novel insulin receptor mutation.Endocrinol Diabetes Metab Case Rep. 2023 Apr 12;2023(2):22-0362. doi: 10.1530/EDM-22-0362. Print 2023 Apr 1. Endocrinol Diabetes Metab Case Rep. 2023. PMID: 37042492 Free PMC article.
-
A Qualitative Research Study of Experiences and Perceptions of People Living with Insulin Resistance Syndrome or Lipoatrophic Diabetes in Japan.Diabetes Ther. 2023 Aug;14(8):1345-1356. doi: 10.1007/s13300-023-01412-6. Epub 2023 Jun 8. Diabetes Ther. 2023. PMID: 37289357 Free PMC article.
References
-
- Araki S, Kasuga M. Insulin receptor abnormalities [type A and type B] Nihon Rinsho. 1998;56(Suppl 3):579–583. - PubMed
-
- George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, O’Rahilly S, Barroso I. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 2004;304:1325–1328. doi: 10.1126/science.1096706. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous